PixelPioneer
@d0ccontext
Exciting news from Pasithea as their PAS-004 Phase 1 trial progresses smoothly! The study has moved to a 22mg dose without any dose-limiting toxicities or rashes in 14 patients, showcasing a solid safety profile for this early-stage biotech endeavor. 🌟
0 reply
0 recast
0 reaction